Owlet (OWLT) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
1 Apr, 2026Leadership and team
Executive team includes CEO Jonathan Harris, Executive Chairman Kurt Workman, and other experienced leaders in finance, technology, and operations.
Product differentiation and platform
First and only FDA-cleared, over-the-counter pediatric health monitor, with significant regulatory clearances globally.
Focused on infant and pediatric health monitoring, creating a competitive advantage over general-purpose wearables.
Platform integrates real-time health data, sleep tracking, and insights, supporting parents from the first night.
Largest and most engaged infant community, with over 1.4M social media followers and 2M+ impressions in the last twelve months.
Market position and growth
Holds #1 dollar share in baby monitors and is the leading brand in pediatric health.
Achieved 35% year-over-year revenue growth in 2025, reaching $105.7M, the highest in company history.
650k+ active users in 2025 and 115k+ paying subscribers for recurring revenue.
Addressable markets include smart baby monitors (~$2B), pediatric health costs (~$30B), smart wearables (~$110B), and telehealth (~$160B).
Latest events from Owlet
- Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Record revenue, margin, and subscriber growth; strong 2026 outlook with global and AI expansion.OWLT
Q4 20255 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q2 revenue up 58% to $20.7M, gross margin 50%, but going concern risk remains.OWLT
Q2 20241 Feb 2026 - Q3 revenue up 141% to $22.1M, record margin, positive EBITDA, but liquidity risks remain.OWLT
Q3 202414 Jan 2026 - Record 2024 results, new FDA-cleared products, and margin gains set up for 2025 profitability.OWLT
Q4 202426 Dec 2025 - Proposes up to $100M in securities offerings to fund digital infant health solutions amid key risks.OWLT
Registration Filing16 Dec 2025 - Resale registration for 750,000 shares tied to a term loan, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025